Health insurance to exclude Novartis's Sebivo tentatively

The Health Insurance Review Agency (HIRA) plans to exclude Novartis Korea's Sebivo tablet (telbivudine), a new treatment for patients with chronic hepatitis B, from the health insurance list until its price can be listed in advanced countries.

In its statement delivered to the HIRA and health ministry, Novartis Korea said in its statement that the health insurance price of Sebivo was already...